Slate Run Pharmaceuticals
Slate Run Pharmaceuticals is a U.S. specialty pharmaceutical company that markets 30+ FDA-approved generic injectable and oral products across multiple therapeutic areas, distributing through Cardinal Health, McKesson, and AmerisourceBergen to U.S. hospitals, pharmacies, and healthcare providers.
- Company typePrivate
- Founded2014
- HeadquartersColumbus, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Slate Run Pharmaceuticals does
Slate Run Pharmaceuticals is a U.S. specialty pharmaceutical company founded in 2014 and headquartered in Columbus, Ohio, focused on supplying generic injectable and oral pharmaceutical products. The company markets more than 30 product families spanning lyophilized powders, sterile solutions, extended-release tablets and capsules, and oral suspensions across antibiotics (vancomycin, azithromycin, doxycycline, tobramycin, ganciclovir), cardiovascular agents (amiodarone, diltiazem, metoprolol, esomeprazole, sodium nitroprusside), MRI/CT contrast agents (gadobutrol, gadoteridol, gadoterate meglumine, iopamidol), CNS treatments (memantine, guanfacine, desvenlafaxine), and antifungals (voriconazole, fluconazole). The operating model is B2B distribution through the three largest U.S. pharmaceutical wholesalers — Cardinal Health, McKesson, and AmerisourceBergen — with direct sales capability for institutional buyers and dedicated customer service operations. Manufacturing covers sterile injectable and complex oral dosage forms, with FDA-approved generic equivalents positioned on consistent supply and quality as primary differentiators. Leadership is led by CEO Michael Plessinger, with a senior team collectively holding over 200 years of generics industry experience.
In February 2026, Slate Run signed an MOU with Arna Pharma Inc. to form a U.S.-based specialty pharmaceutical joint venture, which was finalized on May 14, 2026. The JV combines Arna Pharma's development pipeline with Slate Run's established U.S. commercial, regulatory, and distribution infrastructure, and expanded the company's scope from pure generics into branded products and 505(b)(2) medicines. The JV launched Aridol, its first branded product for respiratory indications, in May 2026, with Bronchitol announced as a follow-on brand launch. Slate Run remains a privately held LLC with no disclosed institutional funding rounds, operating geographies restricted to the United States, and distribution concentrated through the Big 3 wholesaler channel.
Slate Run Pharmaceuticals firmographics
Firmographics- Name
- Slate Run Pharmaceuticals
- Legal name
- Slate Run Pharmaceuticals, LLC
- Website
- https://slaterunpharma.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Slate Run Pharmaceuticals is a U.S. specialty pharmaceutical company that markets 30+ FDA-approved generic injectable and oral products across multiple therapeutic areas, distributing through Cardinal Health, McKesson, and AmerisourceBergen to U.S. hospitals, pharmacies, and healthcare providers.
- Ownership category
- akta.pro rank
Slate Run Pharmaceuticals industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)
- akta.pro secondary industries
- Sterile Injectable Generics (HLAIABAC), Generic Hospital & Institutional Products (HLAIABAL), Specialty Care Pharmaceuticals (HLAIAAAB)
Keywords
Where Slate Run Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Columbus
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Slate Run Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Others
Revenue model
- Generic Pharmaceutical Sales: Revenue generated through sale of FDA-approved generic pharmaceutical products including injectables, tablets, capsules, and oral suspensions across multiple therapeutic areas including antibiotics, cardiovascular agents, contrast agents, and CNS medications. Products sold through wholesale distribution network.
- Branded Products (Post-JV): Following the May 2026 joint venture with Arna Pharma, Slate Run expanded into branded products and 505(b)(2) medicines. First brand product Aridol launched May 2026, with additional branded products expected to follow.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Generic pharmaceutical products - pricing not publicly disclosed |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Slate Run Pharmaceuticals product offering
Product offeringCore offering
Slate Run Pharmaceuticals markets and supplies FDA-approved generic pharmaceutical products, with a core focus on generic injectables (sterile solutions and lyophilized powders) and oral solid and suspension dosage forms. The portfolio spans more than 30 product families across therapeutic areas including antibiotics, cardiovascular agents, MRI/CT contrast agents, CNS, antivirals, and antifungals. In May 2026, the company finalized a joint venture with Arna Pharma Inc. and launched its first branded product, Aridol, expanding into branded and 505(b)(2) specialty medicines.
Product overview
Slate Run Pharmaceuticals is a U.S.-based generic pharmaceutical company founded in 2014, headquartered in Columbus, Ohio. The company markets more than 30 product families spanning generic injectables and oral medications across multiple therapeutic areas including antibiotics, cardiovascular agents, contrast agents, neurological treatments, and antifungals. The portfolio includes generic equivalents of branded drugs such as Vancomycin, Azithromycin, Ganciclovir, and various contrast agents for MRI/CT imaging. In 2026, Slate Run formed a joint venture with Arna Pharma Inc. to expand into branded products and 505(b)(2) medicines, launching Aridol as the first brand product, with Bronchitol expected to follow. The company serves U.S. wholesalers, distributors, pharmacies, and healthcare providers.
Differentiator
Problem solved
Functional benefit
Brands
- Aridol: Brand product launched through joint venture with Arna Pharma Inc. for respiratory indications.
- Bronchitol
Products and services
- Acyclovir Injection, USP
- Amiodarone Hydrochloride Injection, USP Generic antiarrhythmic injection available in 150 mg/3 mL, 450 mg/9 mL, and 900 mg/18 mL concentrations.
- Arformoterol Tartrate Inhalation Solution Generic long-acting beta-agonist inhalation solution for maintenance treatment of COPD, supplied as 15 mcg/2 mL unit-dose vials.
- Azithromycin for Injection, USP Generic macrolide antibiotic injection supplied as lyophilized powder in a 10 mL vial for intravenous administration.
- Bivalirudin for Injection Generic direct thrombin inhibitor for anticoagulation during percutaneous coronary intervention, supplied as 250 mg per vial lyophilized powder.
- Cilostazol Tablets Generic phosphodiesterase III inhibitor for the treatment of intermittent claudication, available in 50 mg and 100 mg tablets.
- Desvenlafaxine Extended-Release Tablets Generic serotonin-norepinephrine reuptake inhibitor for major depressive disorder, available in 25 mg, 50 mg, and 100 mg tablets.
- Dicyclomine Hydrochloride Injection, USP Generic anticholinergic injection for treatment of functional bowel/irritable bowel syndrome, supplied as 20 mg per 2 mL vial.
- Diltiazem Hydrochloride Extended-Release Capsules, USP Generic cardiovascular agent for hypertension and angina, available in 120 mg, 180 mg, and 240 mg capsules.
- Diltiazem Hydrochloride Extended-Release Tablets Generic cardiovascular agent for hypertension, available in 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, and 420 mg tablets.
- DOBUTamine Injection, USP Generic inotropic agent for acute heart failure treatment, supplied as 250 mg/20 mL (12.5 mg/mL) sterile solution.
- Doxycycline for Injection, USP Generic tetracycline antibiotic injection for severe infections, supplied as 100 mg lyophilized powder in 100 mL vial.
- Eptifibatide Injection Generic antiplatelet agent for acute coronary syndrome and PCI, available in 2 mg/mL (20 mg/10 mL) and 0.75 mg/mL (75 mg/100 mL) concentrations.
- Esomeprazole Sodium for Injection Generic proton pump inhibitor for GERD and ulcer treatment, supplied as 40 mg single-dose vials.
- Fluconazole for Oral Suspension USP Generic azole antifungal oral suspension for candidiasis treatment, supplied as 40 mg/mL in 35 mL reconstituted volume.
- Gadobutrol Injection Generic MRI contrast agent (GBCA) for CNS and whole-body imaging, available in 7.5 mL, 10 mL, 15 mL, 30 mL, and 65 mL vials.
- Gadoteridol Injection, USP Generic MRI contrast agent for brain and spine imaging, available in 5 mL, 10 mL, 15 mL, and 20 mL vials.
- Gadoterate Meglumine Injection, USP Generic MRI contrast agent for CNS imaging, available in 2.5 mmol/5 mL, 5 mmol/10 mL, 7.5 mmol/15 mL, 10 mmol/20 mL, and 50 mmol/100 mL vials.
- Ganciclovir for Injection, USP Generic antiviral injection for CMV treatment, supplied as 500 mg lyophilized powder in 10 mL vial.
- Guanfacine Extended-Release Tablets Generic alpha agonist for ADHD treatment, available in 1 mg, 2 mg, 3 mg, and 4 mg tablets.
- Iopamidol Injection, USP (ISOVUE-M) Generic myelographic contrast agent for intrathecal use, available in 41% and 61% concentrations in 10 mL, 15 mL, and 20 mL vials.
- Iopamidol Injection, USP (ISOVUE) Generic contrast agent for angiography and venography, available in 51%, 61%, and 76% concentrations in various vial sizes.
- Leucovorin Calcium for Injection, USP Generic folic acid analog for methotrexate toxicity and megaloblastic anemia, available in 100 mg, 200 mg, 350 mg, and 500 mg vials.
- Memantine Hydrochloride Extended-Release Capsules Generic NMDA inhibitor for Alzheimer's disease treatment, available in 7 mg, 14 mg, 21 mg, and 28 mg capsules.
- Metoprolol Succinate Extended-Release Tablets, USP Generic beta-blocker for hypertension and heart failure, available in 25 mg, 50 mg, 100 mg, and 200 mg tablets.
- Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tablets Generic antihypertensive combination product for blood pressure treatment, available in multiple strength combinations.
- Potassium Chloride Extended-Release Tablets USP Generic electrolyte supplement for hypokalemia treatment, supplied as 20 mEq (1500 mg) tablets.
- Sodium Nitroprusside Injection Generic vasodilator for hypertensive emergencies, supplied as 50 mg per 2 mL vial.
- Sodium Nitroprusside in 0.9% Sodium Chloride Injection Generic vasodilator ready-to-use formulation in saline for hypertensive emergencies, available in 20 mg/100 mL and 50 mg/100 mL concentrations.
- Tobramycin for Injection, USP Generic aminoglycoside antibiotic for severe infections, supplied as 1.2 grams per 100 mL vial sterile solution.
- Trospium Chloride Extended-Release Capsules Generic antimuscarinic for overactive bladder treatment, supplied as 60 mg extended-release capsules.
- Vancomycin Hydrochloride for Injection USP Generic glycopeptide antibiotic for serious infections, available in 500 mg, 1 g, 5 g, and 10 g vial sizes.
- Voriconazole for Injection Generic azole antifungal for invasive aspergillosis treatment, supplied as 200 mg lyophilized powder in 20 mL vial.
- Voriconazole for Oral Suspension Generic azole antifungal oral suspension for fungal infections, supplied as 40 mg/mL in 75 mL reconstituted volume.
- Aridol (Brand Product via Joint Venture with Arna Pharma) First brand product launched through the Arna Pharma-Slate Run joint venture, focused on respiratory indications.
- Bronchitol (Brand Product via Joint Venture with Arna Pharma) Brand respiratory product expected to follow Aridol launch through the Arna Pharma-Slate Run joint venture.
Quantifiable outcome
- 30+ product families marketed across multiple therapeutic areas
- +2 more outcomes
Companies that use Slate Run Pharmaceuticals
Customer profileNamed customers4 records
Segments2 records
Ideal customer profiles3 records
Slate Run Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Slate Run Pharmaceuticals partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Arna Pharma Inc.flagshipArna Pharma Inc. and Slate Run Pharmaceuticals finalized a joint venture in May 2026 to create a scaled-up U.S.-based specialty pharmaceutical company. The partnership combines Arna Pharma's development capabilities and portfolio expansion strategy with Slate Run's established U.S. commercial, regulatory, and supply chain infrastructure. The joint venture focuses on branded products, 505(b)(2) medicines, and specialized generics. The first brand product Aridol was launched together, with additional brand products expected to follow.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
Slate Run Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- B. Braun Medical: B. Braun manufactures and distributes a broad portfolio of sterile injectable pharmaceuticals and IV solutions across U.S. hospitals and clinics. Comparable channel and customer base to Slate Run's hospital-focused injectable franchise.
- Fresenius Kabi USA: Fresenius Kabi USA is one of the largest U.S. suppliers of injectable generics (anti-infectives, anesthetics, critical care) distributed to hospitals and clinics. It is a directly comparable competitor in sterile injectables with overlapping therapeutic categories.
- Lannett Company: Lannett is a U.S. generic pharmaceutical company marketing generic oral solids, liquids, topicals, and select injectables through major wholesalers. Overlapping generics platform with comparable distribution model and pricing dynamics.
- Sagent Pharmaceuticals: Sagent is a U.S.-focused specialty injectable generics company with a similar model of marketing FDA-approved injectable products through the Big-3 wholesale channel. Closely comparable in scale, channel, and product mix.
- ANI Pharmaceuticals: ANI Pharmaceuticals markets generic and specialty branded pharmaceutical products (including sterile injectables) in the U.S. through the same Big-3 wholesalers. Closely comparable mid-sized specialty/generic platform with similar customer mix.
- Amphastar Pharmaceuticals: Amphastar is a U.S. specialty pharmaceutical company focused on injectable, inhalation, and intranasal generics, with a comparable portfolio of complex sterile injectable products marketed through the same Big-3 wholesaler channel. Direct head-to-head competitor in U.S. generic injectables.
- Hikma Pharmaceuticals (Hikma Injectables): Hikma's U.S. injectables division markets a broad portfolio of sterile injectable generics including antibiotics, cardiovascular, and contrast media to U.S. hospitals via major wholesalers. It overlaps directly with most of Slate Run's therapeutic categories and channels.
Emerging players
- Arna Pharma Inc. Arna Pharma is Slate Run's JV partner (May 2026) and a development-focused specialty pharmaceutical company building branded and 505(b)(2) products on top of Slate Run's U.S. infrastructure. Directly comparable strategic model and product pipeline.
Broad incumbents
- Hospira (a Pfizer company): Hospira, now part of Pfizer Injectables, is the dominant U.S. supplier of sterile injectable generics and biosimilars. As a broad incumbent, it competes with Slate Run across nearly every injectable SKU and sets much of the supply and pricing dynamics in U.S. hospitals.
Others
- Cardinal Health (Pharmaceutical Wholesale): Cardinal Health is one of the Big-3 pharmaceutical wholesalers through which Slate Run distributes all of its products. As a channel partner, it shapes accessibility, contract terms, and ultimately Slate Run's ability to scale new launches.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Slate Run Pharmaceuticals social profiles
Digital presenceSlate Run Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Slate Run Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles1 record
Slate Run Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Slate Run Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Slate Run Pharmaceuticals
What does Slate Run Pharmaceuticals do?
Slate Run Pharmaceuticals markets and supplies FDA-approved generic pharmaceutical products, with a core focus on generic injectables (sterile solutions and lyophilized powders) and oral solid and suspension dosage forms. The portfolio spans more than 30 product families across therapeutic areas including antibiotics, cardiovascular agents, MRI/CT contrast agents, CNS, antivirals, and antifungals. In May 2026, the company finalized a joint venture with Arna Pharma Inc. and launched its first branded product, Aridol, expanding into branded and 505(b)(2) specialty medicines.
Is Slate Run Pharmaceuticals a public or private company?
Slate Run Pharmaceuticals is a private company. It is classified as management employee owned and is currently operating.
When was Slate Run Pharmaceuticals founded?
Slate Run Pharmaceuticals was founded in 2014. It employs 11 to 50 people.
Where is Slate Run Pharmaceuticals based?
Slate Run Pharmaceuticals is headquartered in Columbus, United States, in the North America region.
How does Slate Run Pharmaceuticals make money?
Two revenue lines are on record. Generic Pharmaceutical Sales are the primary driver. The others are branded Products (Post-JV).
Who are Slate Run Pharmaceuticals's main competitors?
Direct peers on record are B. Braun Medical, Fresenius Kabi USA, Lannett Company, Sagent Pharmaceuticals, ANI Pharmaceuticals, Amphastar Pharmaceuticals and Hikma Pharmaceuticals (Hikma Injectables). Arna Pharma Inc. is listed as an emerging player. Hospira (a Pfizer company) is listed as a broad incumbent. Cardinal Health (Pharmaceutical Wholesale) is listed as an others.
Does Slate Run Pharmaceuticals have an API?
No public API is recorded for Slate Run Pharmaceuticals.
What industry is Slate Run Pharmaceuticals in?
Slate Run Pharmaceuticals's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAA, Small-Molecule Generics (Branded/Unbranded), with a secondary code of HLAIABAC, Sterile Injectable Generics. Its NAICS code is 32541 and its SIC code is 2834.